Key facts
- HemostOD’s last known valuation is $24.5M (Oct 2025).
- It has raised $7.4M; the latest was Seed Round ($5.4M) in Oct 2025.
- Notable investors include Venture Kick, Ecole Polytechnique Federale de Lausanne, Gold Track, Lichtsteiner Foundation, Orenok Holdings — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for HemostOD
- ·The full record, as it builds
Funding rounds
No funding rounds for HemostOD are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HemostOD
Developer of ex vivo platelets intended to provide a donor-free source of universal platelets. The company generates high quantities of engineered platelets using its bioengineering platform, enabling patients with thrombocytopenia and supporting applications in tissue-targeted cargo delivery, regenerative medicine, and therapeutic stem cell culture.
- Sector
- Healthcare
- HQ
- Saint-Sulpice, Switzerland
- Founded
- 2020
- Employees
- 9
- Website
- hemostod.com/
- Ownership
- Privately Held (backing)
HemostOD doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HemostOD shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HemostOD in its N-PORT filings yet. We sweep new filings monthly.